Next Article in Journal
Great Plasticity in a Great Pathogen: Capsular Types, Virulence Factors and Biofilm Formation in ESBL-Producing Klebsiella pneumoniae from Pediatric Infections in Uruguay
Next Article in Special Issue
Current Therapeutic Approaches for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Infections
Previous Article in Journal
AntiBP3: A Method for Predicting Antibacterial Peptides against Gram-Positive/Negative/Variable Bacteria
Previous Article in Special Issue
Genetic Determinants of Acinetobacter baumannii Serum-Associated Adaptive Efflux-Mediated Antibiotic Resistance
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antibiotics
Volume 13
Issue 2
10.3390/antibiotics13020169
antibiotics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Co-Administration of High-Dose Nebulized Colistin for Acinetobacter baumannii Bacteremic Ventilator-Associated Pneumonia: Impact on Outcomes

by
Ioannis Andrianopoulos
1,
Nikolaos Kazakos
1,
Nikolaos Lagos
1,
Theodora Maniatopoulou
1,
Athanasios Papathanasiou
1,
Georgios Papathanakos
1,
Despoina Koulenti
2,3,*,
Eleni Toli
1,
Konstantina Gartzonika
4 and
Vasilios Koulouras
1
1
Intensive Care Unit, University Hospital of Ioannina, 45500 Ioannina, Greece
2
UQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, QLD 4029, Australia
3
Second Critical Care Department, Attikon University Hospital, Rimini Street, 12462 Athens, Greece
4
Department of Microbiology, University Hospital of Ioannina, 45500 Ioannina, Greece
*
Author to whom correspondence should be addressed.
Antibiotics 2024, 13(2), 169; https://doi.org/10.3390/antibiotics13020169
Submission received: 18 January 2024 / Revised: 4 February 2024 / Accepted: 5 February 2024 / Published: 8 February 2024
(This article belongs to the Special Issue Antibiotic Resistance in Acinetobacter and Associated Treatment Strategies)
Browse Figure
Review Reports Versions Notes

Abstract

:
Acinetobacter baumannii (A. baumannii) is a difficult-to-treat (DTR) pathogen that causes ventilator-associated pneumonia (VAP) associated with high mortality. To improve the outcome of DTR A. Baumannii VAP, nebulized colistin (NC) was introduced with promising but conflicting results on mortality in earlier studies. Currently, NC is used at a much higher daily dose compared to the past. Nevertheless, there is little evidence on the effect of high-dose NC on the outcomes of A. baumannii VAPs, especially in the current era where the percentage of colistin-resistant A. baumannii strains is rising. We conducted a retrospective study comparing bacteremic A. baumannii VAP patients who were treated with and without NC co-administration and were admitted in the Intensive Care Unit of University Hospital of Ioannina from March 2020 to August 2023. Overall, 59 patients (21 and 38 with and without NC coadministration, respectively) were included. Both 28-day and 7-day mortalities were significantly lower in the patient group treated with NC (52.4% vs. 78.9%, p 0.034 and 9.5% vs. 47.4%, p 0.003, respectively). Patients treated with NC had a higher percentage of sepsis resolution by day 7 (38.1% vs. 13.5%, p 0.023) and were more likely to be off vasopressors by day 7 (28.6% vs. 8.1%, p 0.039). The addition of NC in the treatment regime of A. baumannii VAP decreased mortality.

1. Introduction

Acinetobacter baumannii (A. baumannii) is a multi-drug-resistant (MDR) pathogen associated with severe infections, in particular, primary bacteremias, pneumonia and urinary tract infections [1,2]. It is an established difficult-to-treat (DTR) pathogen and its prevalence among hospital infections is rising [3]. Therefore, it is now being considered by the WHO as a critical priority to identify novel treatments for [4]. Mortality in such infections is particularly high among patients with bacteremias, pneumonia or sepsis [5,6,7,8]. It appears that critically ill patients that develop A. baumannii bacteremia due to ventilator-associated pneumonia (VAP) have worse prognosis, especially when they develop septic shock as a complication [9]. And it seems that the emergence of the COVID-19 pandemic has caused a rise in the prevalence of bacterial superinfections from MDR and DTR pathogens [10,11], as well as in the prevalence of VAP as a cause of bacteremia in critically ill patients [12].
Part of the reason for the A. baumannii VAP-associated high mortality is the fact that A. baumannii VAP infections are difficult to treat as therapeutic antibiotic choices are rather limited. In addition, penetration of intravenous antibiotics in the inflamed lung tissue is rather poor for most antibiotics, e.g., colistin b-lactams [13,14]. An attempt to overcome the poor penetration is to increase the dose or reduce the time interval between doses [15], though in cases of higher MIC, even that may not be adequate [16,17]. Therefore, to overcome this, especially in cases of pan-drug-resistant (PDR) pathogens, physicians have pursued combinations of antibiotics, although with conflicting results [18,19,20,21,22,23].
Another strategy to overcome the poor lung tissue penetration in cases of VAP is by using nebulized antimicrobials. Nebulized antimicrobials’ theoretical advantage over the intravenous route is that nebulized antibiotics are delivered directly in the lung alveoli, and both experimental and clinical studies have shown that they offer far better lung tissue concentrations of important antibiotics such as aminoglycosides and colistin compared to the intravenous (IV) route [24,25]. Nebulized colistin, in particular, has been the subject of investigation in VAP from MDR pathogens in a few studies, with conflicting results on its effect on patient outcome. This inconsistency in results has been attributed to the differences in study population, dose of nebulized colistin, co-administration of IV colistin or other intravenous antibiotics and the use of different types of nebulizers [26,27]. In the most recently published meta-analysis, nebulized colistin showed a higher eradication rate but failed to show a statistically significant mortality rate improvement [26]. Nevertheless, there was significant heterogeneity among studies, and there is a need for further trials. This necessity for new trials is highlighted first of all by the fact that currently much higher doses (12–15 million units of colistin per day) than those studied in these earlier studies are used, and the effect of these higher doses on patient outcome is understudied [27].
In addition, as the percentage of DTR and colistin-resistant strains is rising, therapeutic choices become very limited, especially in cases of PDR strains or infections where it is hard to achieve adequate antibiotic concentrations, e.g., VAP and meningitis. In such cases, physicians end up using empirically used combinations of antibiotics, while evidence on the best combination remains scarce [28,29]. In PDR A. baumannii VAP cases, the combination of colistin, tigecycline and high dose sulbactam has showed promising results [30]. Interestingly, other studies also suggest that colistin appears to be the cornerstone of treatment, irrespective of its sensitivity status, especially when cefiderocol is unavailable as is the case in Greece [22]. If such is the case, then colistin is an essential drug in DTR A. baumannii VAP, and therefore, the hypothesis of improving treatment outcomes using adjunct nebulized colistin in addition to IV is raised.
The purpose of our study was to assess the effect of nebulized colistin in addition to the intravenous antibiotics on the mortality and treatment outcome of bacteremic DTR A. baumannii VAP.

2. Results

Overall, from 144 patients with bacteremia from A. baumannii, we identified 70 (48.6%) patients that had VAP as the source of their bacteremia. After excluding patients that received less than 24 h of antibiotics and patients that developed brain death, our analysis included 59 patients (44 male, 15 female) of mean age of 69 ± 9.6 years old. Out of these 59 patients, 21 received nebulized colistin as part of their antibiotic treatment regime (Group A) and 38 did not receive nebulized colistin as part of their antibiotic treatment regime (Group B). Eighteen (18) patients received 5 million units of nebulized colistin every 8 h, 1 patient received 6 million units of nebulized colistin every 8 h, and 2 patients received 3 million units every 8 h.
Baseline characteristics of the two groups of patients with VAP and associated bacteremia due to A. baumannii are shown in Table 1. Overall, there was no statistically significant difference in the baseline characteristics between the subgroup of patients that received combination of IV antibiotics and nebulized colistin (Group A) and the subgroup that received only IV antibiotics (Group B). Patients from Group A and B were of similar age (67.5 ± 9.8 and 67.3 ± 9.6, respectively, ns) and had similar SOFA (3 vs. 3, respectively, ns) and similar APACHE II (19 vs. 20, respectively, ns) scores. There was also no statistically significant difference in comorbidities. Regarding antimicrobial resistance, although Group A patients had a tendency for more resistant strains (a higher percentage of PDR, 28.6% vs. 13.2%, and a higher percentage of colistin resistance, 91.5% vs. 71.1%), altogether the proportion of PDR and colistin-resistant A. baumannii strains did not statistically differ between the two study groups. The great majority of patients were treated with a combination of antibiotics, while 33.3% of Group A patients and 31.6% of Group B patients received a triple combination of antibiotics (no statistical difference). Finally, there was no statistical difference between the two groups regarding the use of intravenous colistin (90.5% Group A vs. 78.9% in Group B, p = 0.258).
The outcomes of both patient groups are shown in Table 2. Overall, the 28-day mortality was 69.5%. Both all-cause 28-day mortality and 28-day mortality related to A. baumannii infection were significantly lower in the group of patients that received nebulized colistin: all-cause 28-day mortality was 52.4% in Group A vs. 78.9% in Group B, p 0.034, and 28-day mortality attributed to A. baumannii was 40% vs. 73.5% in Group A and B, respectively, p 0.025) (Figure 1).
Group A patients receiving nebulized colistin also had a significantly reduced 7-day mortality (9.5% vs. 47.4%, p = 0.003), a shorter resolution of sepsis by day 7 (38.1% vs. 13.5%, p = 0.023) and were more likely to be without the need for vasopressors by day 7 (28.6% vs. 8.1%, p = 0.039). Among the two groups, there was no statistical difference in terms of complications, i.e., acute respiratory distress syndrome, coagulopathy, liver dysfunction and sepsis. Patients that were not treated with nebulized colistin had a tendency to develop more frequent septic shock, though results failed to reach statistical significance (66.7% in Group A vs. 86.8% in Group B patients, p = 0.065). Regarding safety considerations, colistin treatment was generally well-tolerated in both patient groups, and only in one patient in Group B, intravenous colistin was discontinued prematurely due to nephrotoxicity; the development of acute kidney injury and the need for renal replacement therapy was similar in both groups (33.3% in Group A vs. 40% in Group B, p = 0.587).
Finally, we performed a sensitivity analysis using a propensity score analysis. A propensity score covariate was formed and adjusted for baseline characteristics (age, disease severity and comorbidities), and a multivariate binary logistic regression analysis was performed, that included the propensity score covariate, with the PDR, nebulized colistin and high dose ampicillin/sulbactam used as covariates. The analysis showed that nebulized colistin was an independent risk factor for mortality (Supplemental Table S1).

3. Discussion

Our study of 59 critically ill patients with DTR A. baumannii VAP and associated bacteremia showed that the co-administration of nebulized colistin in the standard treatment regime was accompanied by a reduction in the 28-day all-cause mortality (52.4% vs. 78.9%, p = 0.025). It also showed that the 28-day mortality attributed to DTR A. baumannii and the 7-day mortality were significantly lower in the patient group treated with nebulized colistin (40% and 9.5% vs. 73.5% and 47.4%, respectively). An important finding of our study was also that those patients treated with nebulized colistin were more likely to be off vasopressors by day 7 (28.6% vs. 8.1%) and were more likely to have resolution of their sepsis by day 7 (38.1% vs. 13.5%, respectively). Interestingly, the great majority of patients (90.5% Group A, 71.1% Group B) had VAP from colistin-resistant A. baumannii. Also, as expected by the PK characteristics of nebulized colistin and in line with previous studies, the beneficial effects of nebulized colistin co-administration were not accompanied by an increased incidence of acute kidney injury and need for renal replacement therapy [31,32].
To the best of our knowledge, this is the first study that shows improvement in mortality in patients with bacteremic A. baumannii VAP receiving nebulized colistin in addition to an intravenous antibiotic regime that, in the vast majority of cases, includes colistin. Two previous studies, the study of Tumbarello et al. and the study of Korbila et al., did show a higher clinical cure rate in the nebulized group but failed to show improvement in mortality [33,34]. A possible explanation for this difference compared to our study might be the low dose of nebulized colistin used in both studies (<3 million units/day) compared to the high dose of 15 million units/day used in our study. Another important difference between our study and the two previous studies was the sensitivity pattern of A. baumannii. Specifically, in the studies of Tumbarello et al. and Korbila et al., A. baumannii strains were colistin-sensitive, while the majority of the strains in our study were colistin-resistant, and possibly, the addition of nebulized colistin in our cohort, with its associated significant increase in concentration in the epithelial lining fluid, might have made the difference in the overall efficacy of the combined regime. Finally, another factor explaining the difference in mortality outcomes might be the fact that the majority of our patients had COVID-19 pneumonia on ICU admission (90.5% Group A, 89.5% Group B). COVID-19 patients have a diffuse disease of their lung parenchyma and are more vulnerable to superinfections as a significant part of their lung parenchyma is diseased. The addition of nebulized colistin in these patients might significantly enhance the action of colistin compared to non-COVID-19 patients. Unfortunately, the number of non-COVID-19 patients with bacteremic VAP was very low (10%), and no comparison could have been made between COVID-19 and non-COVID-19 patients with bacteremic VAP.
Our study showed that patients receiving nebulized colistin also demonstrated improved 7-day outcomes, in terms of mortality as well as sepsis resolution and weaning off the vasopressors. This is in accordance with most previous studies that have showed better clinical response in patients receiving nebulized colistin [33,34,35,36]. The improvement in 7-day mortality better reflects the outcome of the infection as it is closer to the onset of the infection compared to day 28 [12].
Finally, to the best of our knowledge, our study is the largest one reporting results on the effect of nebulized colistin in colistin-resistant A. baumannii VAP, while most studies usually exclude patients with colistin-resistant A. baumannii [35]. There are only two other studies addressing this issue in PDR A. baumannii patients with VAP: the first is a case series study of 10 patients, who received nebulized and intravenous colistin, high-dose tigecycline and high-dose ampicillin/sulbactam, which showed a very good clinical outcome; and the second one recruited 32 patients with PDR A. baumannii VAP: 10 patients were treated with the above mentioned triple antibiotic combination (80% also received fosfomycin) and 22 patients received a combination of two antibiotics (details were not mentioned) [30,37]. The latter study also reported a favorable outcome with improved survival. Therefore, all three studies show a favorable outcome in patients with colistin-resistant VAP treated with nebulized colistin. As colistin resistance of A. baumannii strains continues to rise and new antibiotics such as cefiderocol are not yet widely available across countries (as it was also not available in our country during the study period), more studies addressing the effect of colistin nebulization in colistin-resistant A. baumannii VAP are urgently needed.

3.1. Limitations

Our study has limitations. First of all, as a retrospective single center study, it is subject to the inherent limitations of such studies. Our study sample is not large; however, it is similar to most studies published on the same subject [27]. Also, the majority of our cohort were COVID-19 patients, and one might argue that more data from non-COVID-19 patients are needed before we extrapolate our conclusions to a non-COVID-19 ICU population. Nevertheless, there is currently no evidence that COVID-19 patients respond differently to nebulized antibiotics. In addition, the A. baumannii strains of our cohort were mostly colistin-resistant, and our results might not be generalizable in different settings. Also, there was no record in patient data about which nebulizer was used in each particular patient (nebulized colistin was delivered either with vibrating mesh or jet nebulizer). Nevertheless, despite the fact that, in most cases, a jet nebulizer was used, which is known to provide nebulization in the least optimal way, [38] our study had a positive outcome for nebulized colistin. Finally, as cefiderocol was not available in our country during the study period, our results may not be generalizable in patients receiving cefiderocol as part of their therapeutic regime; nevertheless, results are conflicting regarding cefiderocol’s superiority over colistin for such infections [39].

3.2. Strengths

To the best of our knowledge, this is the first study comparing patients receiving either a combination of both intravenous and high-dose nebulized colistin or intravenous colistin only. It is also the first study showing improvement in mortality outcomes. Moreover, in most previous studies, nebulized colistin was administered in critically ill patients with gram negative infections attributed to colistin-sensitive A. baumannii, while in our study, most patients had colistin-resistant A. baumannii; nearly 30% of Group A patients had PDR A. baumannii. The presence of a significant percentage of colistin-resistant and PDR A. baumannii strains reflects the current (unfortunate) reality in a significant number of ICUs in several countries globally as it has been shaped since the COVID-19 pandemic. The emergence of colistin resistance or failure in particular could be related to subtherapeutic levels of colistin in patients, underlining perhaps the importance of using nebulized colistin in VAP [40].

4. Materials and Methods

We conducted a retrospective, single center, observational study that included all patients with bacteremic VAP due to A. baumannii who were admitted in the two intensive care units (ICU) of Ioannina University Hospital from March 2020 to August 2023. University Hospital of Ioannina is a 900-bed academic hospital in Ioannina, Greece. Data were collected in an anonymized way, and data collection was approved by the institutional review board of the University Hospital of Ioannina (protocol number 37/2023). Due to the retrospective, observational nature of the study, the need for informed consent was waived.

4.1. Data Collection and Patient Groups

We recorded information on comorbidities, sex, age, severity of disease, including severity of disease scores on admission such as the Sequential Organ Failure Assessment (SOFA) and the Acute Physiologic Assessment and Chronic Health Evaluation (APACHE) II. We also recorded the SOFA score the previous day of sepsis onset, on the day of sepsis development and on day 7 since the development of sepsis. In addition, we recorded complications, including acute respiratory distress syndrome (ARDS), acute kidney injury (AKI), the application of continuous renal replacement therapy (CRRT), coagulopathy, sepsis, septic shock and hepatic dysfunction. We also recorded 7-day outcomes such as resolution of sepsis, discontinuation of vasopressors and microbiological cure, and long term outcomes such as 28-day mortality, association of death with the A. baumannii infection, antibiotic sensitivities and the type, dose and duration of antibiotics administered, ICU length of stay (LOS) and duration of mechanical ventilation. Patients that did not receive antibiotics with potential action against A. baumannii or received antibiotics for less than 24 h were excluded from our study. In patients with more than one episode of bacteremia from A. baumannii, only the first episode was recorded.
Patients were categorized into two groups: in Group A were patients with VAP and a secondary A. baumannii bacteremia that received nebulized colistin as part of their antibiotic treatment regime, and in Group B were patients with VAP and a secondary A. baumannii bacteremia that did not receive nebulized colistin as part of their antibiotic treatment regime.

4.2. Study Outcomes

The primary outcomes of the study were 28-day total mortality and 28-day mortality related to the A. baumannii infection. Secondary outcomes included the development of sepsis, the 7-day mortality, the 7-day resolution of sepsis, the 7-day need for vasopressors, the 7-day microbiological cure, the length of stay in the ICU and in the hospital, the duration of mechanical ventilation and the development of complications-organ failures.

4.3. Definitions

We defined ventilator-associated pneumonia (VAP) by the Centers for Disease Control and Prevention (CDC) criteria [41]. SEPSIS-3 definition was used to define sepsis and septic shock [42]. The Berlin definition was used to define ARDS [43]. For patients already diagnosed with ARDS on admission, both a worsening of the severity of the ARDS stage and a deterioration of the lung opacities were considered as new ARDS complicating the A. baumannii VAP [43]. We defined acute kidney injury (AKI) based on the ‘Kidney Disease: Improving Global Outcomes’ (KDIGO) guidelines [44]. Hepatic dysfunction was defined, as previously described, as total bilirubin greater than 2 mg/dL [12]. Coagulopathy was defined as, either a platelet count of less than 150,000/μL, or an International Normalized Ratio (INR) of more than 1.4 [45]. Death was attributed to A. baumannii if at least two ICU physicians concluded that the patient died from the A. baumannii-studied VAP. A SOFA score on day 7 from sepsis less or equal to the 24 h before sepsis SOFA score was defined as resolution of sepsis [41]. Microbiological cure was defined as a negative blood culture result for A. baumannii in a subsequent blood culture taken up to day 7 post the episode of bacteremia. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) minimum inhibitory capacity (MIC) breakpoints were used to determine sensitivity of antibiotics [46]. MIC for colistin and tigecycline were determined by using broth microdilution, while for the rest of antibiotics the VITEK© system was used. DTR was defined as A. baumannii resistant to all first class antibiotics (beta-lactams, including carbapenems and fluoroquinolones [47].

4.4. Statistical Analysis

Statistical analysis was performed as previously described [12]. The Kolgomorov–Smirnov test was used to assess for normal distribution of continuous variables, and variables were presented as either median, min–max or mean ± standard deviation values as appropriate. The study groups were compared for the continuous variables either by the t-test or Mann–Whitney test for the continuous variables whereas, for categorical variables, χ2 tests (p-values were extracted from Fisher’s exact test) were applied. The log-rank test was used to construct and compare the Kaplan–Meier survival curves of the two groups, after the proportionality of hazards was assessed graphically and confirmed for all covariates. A p-value of less than 0.05 was used to define statistical significance in all cases. A sensitivity analysis was performed using propensity score analysis. A propensity score was adjusted for baseline characteristics (age, severity of disease, comorbidities) and used as covariate in binary logistic regression analysis to assess for risk factors of mortality. SPSS® 29.0 was used for all statistical analyses.

5. Conclusions

The addition of high-dose nebulized colistin to the standard intravenous treatment of critically ill patients with bacteremic A. baumannii VAP seems to improve patients’ outcome. The co-administration of high-dose nebulized colistin appears to be both beneficial and safe irrespective of the in vitro sensitivity of colistin against A. baumannii.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/antibiotics13020169/s1, Table S1: Propensity score-adjusted analysis on A. baumannii attributed mortality.

Author Contributions

Conceptualization, I.A.; methodology, I.A. and A.P.; software, A.P.; validation, I.A., T.M., N.L., N.K. and A.P.; formal analysis, I.A. and A.P.; investigation, I.A., T.M., N.L., N.K., E.T., G.P., K.G. and A.P.; resources, K.G., I.A., T.M., N.L., N.K. and A.P.; data curation, I.A., T.M., N.L., E.T., N.K., D.K., G.P., K.G. and A.P.; writing—original draft preparation, I.A., A.P., D.K. and G.P.; writing—review and editing, I.A., T.M., N.L., N.K., K.G., A.P., E.T., D.K., V.K. and G.P.; visualization, A.P.; supervision, I.A. and V.K. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of the University Hospital of Ioannina (protocol code 37/2023 and date of approval).

Informed Consent Statement

Patient consent was waived due to the retrospective and observational nature of the study.

Data Availability Statement

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Acknowledgments

Vassiliki Stamati for technical support and Maria Mpaziou for administrative support.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Cavallo, I.; Oliva, A.; Pages, R.; Sivori, F.; Truglio, M.; Fabrizio, G.; Pasqua, M.; Pimpinelli, F.; Di Domenico, E.G. Acinetobacter baumannii in the critically ill: Complex infections get complicated. Front. Microbiol. 2023, 14, 1196774. [Google Scholar] [CrossRef]
  2. Koulenti, D.; Vandana, K.E.; Rello, J. Current viewpoint on the epidemiology of nonfermenting Gram-negative bacterial strains. Curr. Opin. Infect. Dis. 2023, 36, 545–554. [Google Scholar] [CrossRef]
  3. Scaglione, V.; Reale, M.; Davoli, C.; Mazzitelli, M.; Serapide, F.; Lionello, R.; La Gamba, V.; Fusco, P.; Bruni, A.; Procopio, D.; et al. Prevalence of Antibiotic Resistance Over Time in a Third-Level University Hospital. Microb. Drug Resist. 2022, 28, 425–435. [Google Scholar] [CrossRef]
  4. Tacconelli, E.; Carrara, E.; Savoldi, A.; Harbarth, S.; Mendelson, M.; Monnet, D.L.; Pulcini, C.; Kahlmeter, G.; Kluytmans, J.; Carmeli, Y.; et al. Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect. Dis. 2018, 18, 318–327. [Google Scholar] [CrossRef]
  5. Russo, A.; Bassetti, M.; Ceccarelli, G.; Carannante, N.; Losito, A.R.; Bartoletti, M.; Corcione, S.; Granata, G.; Santoro, A.; Giacobbe, D.R.; et al. Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: Clinical features, therapy and outcome from a multicenter study. J. Infect. 2019, 79, 130–138. [Google Scholar] [CrossRef]
  6. Du, X.; Xu, X.; Yao, J.; Deng, K.; Chen, S.; Shen, Z.; Yang, L.; Feng, G. Predictors of mortality in patients infected with carbapenem-resistant Acinetobacter baumannii: A systematic review and meta-analysis. Am. J. Infect. Control 2019, 47, 1140–1145. [Google Scholar] [CrossRef]
  7. Zhou, H.; Yao, Y.; Zhu, B.; Ren, D.; Yang, Q.; Fu, Y.; Yu, Y.; Zhou, J. Risk factors for acquisition and mortality of multidrug-resistant Acinetobacter baumannii bacteremia: A retrospective study from a Chinese hospital. Medicine 2019, 98, e14937. [Google Scholar] [CrossRef]
  8. Adukauskiene, D.; Ciginskiene, A.; Adukauskaite, A.; Koulenti, D.; Rello, J. Clinical Features and Outcomes of Monobacterial and Polybacterial Episodes of Ventilator-Associated Pneumonia Due to Multidrug-Resistant Acinetobacter baumannii. Antibiotics 2022, 11, 892. [Google Scholar] [CrossRef]
  9. Agbaht, K.; Diaz, E.; Muñoz, E.; Lisboa, T.; Gomez, F.; Depuydt, P.O.; Blot, S.I.; Rello, J. Bacteremia in patients with ventilator-associated pneumonia is associated with increased mortality: A study comparing bacteremic vs. nonbacteremic ventilator-associated pneumonia. Crit. Care Med. 2007, 35, 2064–2070. [Google Scholar] [CrossRef]
  10. Loyola-Cruz, M.Á.; Gonzalez-Avila, L.U.; Martínez-Trejo, A.; Saldaña-Padilla, A.; Hernández-Cortez, C.; Bello-López, J.M.; Castro-Escarpulli, G. ESKAPE and Beyond: The Burden of Coinfections in the COVID-19 Pandemic. Pathogens 2023, 12, 743. [Google Scholar] [CrossRef]
  11. Segala, F.V.; Pafundi, P.C.; Masciocchi, C.; Fiori, B.; Taddei, E.; Antenucci, L.; De Angelis, G.; Guerriero, S.; Pastorino, R.; Damiani, A.; et al. Incidence of bloodstream infections due to multidrug-resistant pathogens in ordinary wards and intensive care units before and during the COVID-19 pandemic: A real-life, retrospective observational study. Infection 2023, 51, 1061–1069. [Google Scholar] [CrossRef]
  12. Andrianopoulos, I.; Maniatopoulou, T.; Lagos, N.; Kazakos, N.; Papathanasiou, A.; Papathanakos, G.; Koulenti, D.; Kittas, C.; Koulouras, V. Acinetobacter baumannii Bloodstream Infections in the COVID-19 Era: A Comparative Analysis between COVID-19 and Non-COVID-19 Critically Ill Patients. Microorganisms 2023, 11, 1811. [Google Scholar] [CrossRef]
  13. Finazzi, S.; Luci, G.; Olivieri, C.; Langer, M.; Mandelli, G.; Corona, A.; Viaggi, B.; Di Paolo, A. Tissue Penetration of Antimicrobials in Intensive Care Unit Patients: A Systematic Review—Part I. Antibiotics 2022, 11, 1164. [Google Scholar] [CrossRef]
  14. Viaggi, B.; Cangialosi, A.; Langer, M.; Olivieri, C.; Gori, A.; Corona, A.; Finazzi, S.; Di Paolo, A. Tissue Penetration of Antimicrobials in Intensive Care Unit Patients: A Systematic Review—Part II. Antibiotics 2022, 11, 1193. [Google Scholar] [CrossRef]
  15. Bassetti, M.; Luyt, C.-E.; Nicolau, D.P.; Pugin, J. Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patient. Ann. Intensive Care 2016, 6, 35. [Google Scholar] [CrossRef]
  16. Leng, B.; Yan, G.; Wang, C.; Shen, C.; Zhang, W.; Wang, W. Dose optimisation based on pharmacokinetic/pharmacodynamic target of tigecycline. J. Glob. Antimicrob. Resist. 2021, 25, 315–322. [Google Scholar] [CrossRef]
  17. De Pascale, G.; Lisi, L.; Ciotti, G.M.P.; Vallecoccia, M.S.; Cutuli, S.L.; Cascarano, L.; Gelormini, C.; Bello, G.; Montini, L.; Carelli, S.; et al. Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections. Ann. Intensive Care 2020, 10, 94. [Google Scholar] [CrossRef]
  18. Mantzana, P.; Protonotariou, E.; Kassomenaki, A.; Meletis, G.; Tychala, A.; Keskilidou, E.; Arhonti, M.; Katsanou, C.; Daviti, A.; Vasilaki, O.; et al. In Vitro Synergistic Activity of Antimicrobial Combinations against Carbapenem- and Colistin-Resistant Acinetobacter baumannii and Klebsiella pneumoniae. Antibiotics 2023, 12, 93. [Google Scholar] [CrossRef]
  19. Wang, S.-H.; Yang, K.-Y.; Sheu, C.-C.; Lin, Y.-C.; Chan, M.-C.; Feng, J.-Y.; Chen, C.-M.; Chen, C.-Y.; Zheng, Z.-R.; Chou, Y.-C.; et al. The prevalence, presentation and outcome of colistin susceptible-only Acinetobacter Baumannii-associated pneumonia in intensive care unit: A multicenter observational study. Sci. Rep. 2023, 13, 140. [Google Scholar] [CrossRef]
  20. Yang, K.-Y.; Peng, C.-K.; Sheu, C.-C.; Lin, Y.-C.; Chan, M.-C.; Wang, S.-H.; Chen, C.-M.; Chen, C.-Y.; Zheng, Z.-R.; Feng, J.-Y.; et al. Clinical effectiveness of tigecycline in combination therapy against nosocomial pneumonia caused by CR-GNB in intensive care units: A retrospective multi-centre observational study. J. Intensive Care 2023, 11, 1. [Google Scholar] [CrossRef]
  21. Heil, E.L.; Claeys, K.C.; Kline, E.G.; Rogers, T.M.; Squires, K.M.; Iovleva, A.; Doi, Y.; Banoub, M.; Noval, M.M.; Luethy, P.M.; et al. Early initiation of three-drug combinations for the treatment of carbapenem-resistant A. baumannii among COVID-19 patients. J. Antimicrob. Chemother. 2023, 78, 1034–1040. [Google Scholar] [CrossRef]
  22. Dickstein, Y.; Lellouche, J.; Ben Dalak Amar, M.; Schwartz, D.; Nutman, A.; Daitch, V.; Yahav, D.; Leibovici, L.; Skiada, A.; Antoniadou, A.; et al. Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial. Clin. Infect. Dis. 2019, 69, 769–776. [Google Scholar] [CrossRef]
  23. Kaye, K.S.; Marchaim, D.; Thamlikitkul, V.; Carmeli, Y.; Chiu, C.-H.; Daikos, G.; Dhar, S.; Durante-Mangoni, E.; Gikas, A.; Kotanidou, A.; et al. Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms. NEJM Evid. 2023, 2, EVIDoa2200131. [Google Scholar] [CrossRef]
  24. De Pascale, G.; Pintaudi, G.; Lisi, L.; De Maio, F.; Cutuli, S.L.; Tanzarella, E.S.; Carelli, S.; Lombardi, G.; Cesarano, M.; Gennenzi, V.; et al. Use of High-Dose Nebulized Colistimethate in Patients with Colistin-Only Susceptible Acinetobacter baumannii VAP: Clinical, Pharmacokinetic and Microbiome Features. Antibiotics 2023, 12, 125. [Google Scholar] [CrossRef]
  25. Heffernan, A.J.; Sime, F.B.; Lipman, J.; Dhanani, J.; Andrews, K.; Ellwood, D.; Grimwood, K.; Roberts, J.A. Intrapulmonary pharmacokinetics of antibiotics used to treat nosocomial pneumonia caused by Gram-negative bacilli: A systematic review. Int. J. Antimicrob. Agents 2019, 53, 234–245. [Google Scholar] [CrossRef]
  26. Zhang, X.; Cui, X.; Jiang, M.; Huang, S.; Yang, M. Nebulized colistin as the adjunctive treatment for ventilator-associated pneumonia: A systematic review and meta-analysis. J. Crit. Care 2023, 77, 154315. [Google Scholar] [CrossRef]
  27. Karaiskos, I.; Gkoufa, A.; Polyzou, E.; Schinas, G.; Athanassa, Z.; Akinosoglou, K. High-Dose Nebulized Colistin Methanesulfonate and the Role in Hospital-Acquired Pneumonia Caused by Gram-Negative Bacteria with Difficult-to-Treat Resistance: A Review. Microorganisms 2023, 11, 1459. [Google Scholar] [CrossRef]
  28. Papathanakos, G.; Andrianopoulos, I.; Papathanasiou, A.; Koulenti, D.; Gartzonika, K.; Koulouras, V. Pandrug-resistant Acinetobacter baumannii treatment: Still a debatable topic with no definite solutions. J. Antimicrob. Chemother. 2020, 75, 3081. [Google Scholar] [CrossRef]
  29. Karakonstantis, S.; Kritsotakis, E.I.; Gikas, A. Pandrug-resistant Gram-negative bacteria: A systematic review of current epidemiology, prognosis and treatment options. J. Antimicrob. Chemother. 2020, 75, 271–282. [Google Scholar] [CrossRef]
  30. Assimakopoulos, S.F.; Karamouzos, V.; Lefkaditi, A.; Sklavou, C.; Kolonitsiou, F.; Christofidou, M.; Fligou, F.; Gogos, C.; Marangos, M. Triple combination therapy with high-dose ampicillin/sulbactam, high-dose tigecycline and colistin in the treatment of ventilator-associated pneumonia caused by pan-drug resistant Acinetobacter baumannii: A case series study. Infez. Med. 2019, 27, 11–16. [Google Scholar]
  31. Min, K.L.; Son, E.S.; Kim, J.S.; Kim, S.H.; Jung, S.M.; Chang, M.J. Risk factors of colistin safety according to administration routes: Intravenous and aerosolized colistin. PLoS ONE 2018, 13, e0207588. [Google Scholar] [CrossRef] [PubMed]
  32. Park, S.Y.; Park, M.S.; Chung, C.R.; Kim, J.S.; Park, S.J.; Lee, H.B. Clinical Effectiveness and Nephrotoxicity of Aerosolized Colistin Treatment in Multidrug-Resistant Gram-Negative Pneumonia. Korean J. Crit. Care Med. 2016, 31, 208–220. [Google Scholar] [CrossRef]
  33. Tumbarello, M.; De Pascale, G.; Trecarichi, E.M.; De Martino, S.; Bello, G.; Maviglia, R.; Spanu, T.; Antonelli, M. Effect of Aerosolized Colistin as Adjunctive Treatment on the Outcomes of Microbiologically Documented Ventilator-Associated Pneumonia Caused by Colistin-Only Susceptible Gram-Negative Bacteria. Chest 2013, 144, 1768–1775. [Google Scholar] [CrossRef]
  34. Korbila, I.P.; Michalopoulos, A.; Rafailidis, P.I.; Nikita, D.; Samonis, G.; Falagas, M.E. Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: A comparative cohort study. Clin. Microbiol. Infect. 2010, 16, 1230–1236. [Google Scholar] [CrossRef]
  35. Feng, J.-Y.; Huang, J.-R.; Lee, C.-C.; Tseng, Y.-H.; Pan, S.-W.; Chen, Y.-M.; Yang, K.-Y. Role of nebulized colistin as a substitutive strategy against nosocomial pneumonia caused by CR-GNB in intensive care units: A retrospective cohort study. Ann. Intensive Care 2023, 13, 1. [Google Scholar] [CrossRef]
  36. Kim, Y.K.; Lee, J.H.; Lee, H.-K.; Chung, B.C.; Yu, S.J.; Lee, H.-Y.; Park, J.-H.; Kim, S.; Kim, H.-K.; Kiem, S.; et al. Efficacy of nebulized colistin-based therapy without concurrent intravenous colistin for ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii. J. Thorac. Dis. 2017, 9, 555–567. [Google Scholar] [CrossRef]
  37. Casarotta, E.; Bottari, E.; Vannicola, S.; Giorgetti, R.; Domizi, R.; Carsetti, A.; Damiani, E.; Scorcella, C.; Gabbanelli, V.; Pantanetti, S.; et al. Antibiotic Treatment of Acinetobacter baumannii Superinfection in Patients With SARS-CoV-2 Infection Admitted to Intensive Care Unit: An Observational Retrospective Study. Front. Med. 2022, 9, 910031. [Google Scholar] [CrossRef]
  38. The European Investigators Network for Nebulized Antibiotics in Ventilator-associated Pneumonia; Rouby, J.J.; Sole-Lleonart, C.; Rello, J. Ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria: Understanding nebulization of aminoglycosides and colistin. Intensive Care Med. 2020, 46, 766–770. [Google Scholar] [CrossRef]
  39. Mazzitelli, M.; Gregori, D.; Sasset, L.; Trevenzoli, M.; Scaglione, V.; Lo Menzo, S.; Marinello, S.; Mengato, D.; Venturini, F.; Tiberio, I.; et al. Cefiderocol-Based versus Colistin-Based Regimens for Severe Carbapenem-Resistant Acinetobacter baumannii Infections: A Propensity Score-Weighted, Retrospective Cohort Study during the First Two Years of the COVID-19 Pandemic. Microorganisms 2023, 11, 984. [Google Scholar] [CrossRef]
  40. Marano, V.; Marascio, N.; Pavia, G.; Lamberti, A.G.; Quirino, A.; Musarella, R.; Casalinuovo, F.; Mazzitelli, M.; Trecarichi, E.M.; Torti, C.; et al. Identification of pmrB mutations as putative mechanism for colistin resistance in A. baumannii strains isolated after in vivo colistin exposure. Microb. Pathog. 2020, 142, 104058. [Google Scholar] [CrossRef]
  41. Magill, S.S.; Klompas, M.; Balk, R.; Burns, S.M.; Deutschman, C.S.; Diekema, D.; Fridkin, S.; Greene, L.; Guh, A.; Gutterman, D.; et al. Developing a New, National Approach to Surveillance for Ventilator-Associated Events. Crit. Care Med. 2013, 41, 2467–2475. [Google Scholar] [CrossRef]
  42. Singer, M.; Deutschman, C.S.; Seymour, C.W.; Shankar-Hari, M.; Annane, D.; Bauer, M.; Bellomo, R.; Bernard, G.R.; Chiche, J.-D.; Coopersmith, C.M.; et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016, 315, 801. [Google Scholar] [CrossRef] [PubMed]
  43. Ranieri, V.I.T.O.; Rubenfeld, G.D.; Thompson, B.T.; Ferguson, N.D.; Caldwell, E.; Fan, E.; Camporota, L. Acute Respiratory Distress Syndrome: The Berlin Definition. JAMA 2012, 307, 2526–2533. [Google Scholar] [CrossRef] [PubMed]
  44. Kellum, J.A.; Lameire, N.; KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: A KDIGO summary (Part 1). Crit. Care 2013, 17, 204. [Google Scholar] [CrossRef]
  45. Perez Ruiz de Garibay, A.; Kortgen, A.; Leonhardt, J.; Zipprich, A.; Bauer, M. Critical care hepatology: Definitions, incidence, prognosis and role of liver failure in critically ill patients. Crit. Care 2022, 26, 289. [Google Scholar] [CrossRef]
  46. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 13.1. 2023. Available online: http://www.eucast.org (accessed on 10 December 2023).
  47. Kadri, S.S.; Adjemian, J.; Lai, Y.L.; Spaulding, A.B.; Ricotta, E.; Prevots, D.R.; Palmore, T.N.; Rhee, C.; Klompas, M.; Dekker, J.P.; et al. Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents. Clin. Infect. Dis. 2018, 67, 1803–1814. [Google Scholar] [CrossRef]
Antibiotics 13 00169 g001
Figure 1. Probability of survival for the first 28 days post Acinetobacter baumannii bacteremic VAP was significantly higher for patients receiving nebulized colistin (Group A) vs. patients not receiving nebulized colistin as part of their therapeutic regime.
Figure 1. Probability of survival for the first 28 days post Acinetobacter baumannii bacteremic VAP was significantly higher for patients receiving nebulized colistin (Group A) vs. patients not receiving nebulized colistin as part of their therapeutic regime.
Antibiotics 13 00169 g001
Table 1. Baseline characteristics of the patients with bacteremic VAP from Acinetobacter baumannii that were treated (Group A) and not treated (Group B) with nebulized colistin.
Table 1. Baseline characteristics of the patients with bacteremic VAP from Acinetobacter baumannii that were treated (Group A) and not treated (Group B) with nebulized colistin.
ParameterGroup A
(Treated with
Nebulized
Colistin)
(n = 21)		Group B
(Treated without
Nebulized)
Colistin
(n = 38)		p-Value
Age (mean ± SD)67.5 ± 9.867.3 ± 9.60.657
Gender (male n, %)15 (71.4%)29 (76.3%)0.680
APACHE II median (min–max)19 (12–35)20 (12–47)0.934
CCI ∞ median (min–max)3 (1–9)3 (0–8)0.898
SOFA ∞ score median (min–max)4 (3–11)4 (2–17)0.798
COVID 19 (n, %)19 (90.5%)34 (89.5%)0.903
Comorbidities
Diabetes mellitus (n, %)10 (47.6%)14 (36.8%)0.420
Heart failure (n, %)1 (4.8%)2 (5.3%)0.933
Coronary Heart Disease (n, %)3 (14.3%)3 (7.9%)0.437
Chronic Kidney Disease (n, %)1 (4.8%)3 (7.9%)0.647
Cirrhosis (n, %)1 (4.8%)0 (0%)0.175
COPD ∞ (n, %)3 (14.3%)5 (13.2%)0.904
Obesity (n, %)4 (19%)5 (13.2%)0.547
Cancer (n, %)0(0%)(4 10.5%)0.124
Infection parameters
PDR ∞6 (28.6%)5 (13.2%)0.146
Colistin sensitive2 (9.5%)11 (28.9%)0.085
Colistin treated19 (90.5%)30 (78.9%)0.258
Patient was treated with:
Monotherapy0 (0)2 (5.3%)0.443
2 drugs10 (47.6%)21 (55.3%)
3 drugs7 (33.3%)12 (31.6%)
4 drugs4 (19%)3 (7.9%)
Antibiotics
Tigecycline (n, %)21 (100%)37 (97.4%)-1
High dose ampicillin/sulbactam (n, %)13 (62%)8 (28.1%)0.064
Meropenem (n, %)7 (33.3%)15 (39.5%)0.781
Fosfomycin (n, %)3 (14.3%)4 (10.5%)0.69
Appropriate antibiotic treatment in shock ∫17 (85%)35 (97.2%)0.089
∞ CCI: Charlson Comorbidity Index; SOFA, Sequential Organ Failure Assessment score; COPD, Chronic Obstructive Pulmonary Disease; PDR, pan-drug-resistant. ∫ The patient at the time of developing septic shock was already on or was started on antibiotics targeting A. baumannii.
Table 2. Outcome and complications of the patients with bacteremic VAP from Acinetobacter baumannii that were treated (Group A) and not treated (Group B) with nebulized colistin.
Table 2. Outcome and complications of the patients with bacteremic VAP from Acinetobacter baumannii that were treated (Group A) and not treated (Group B) with nebulized colistin.
ParameterGroup A
(Treated with
Nebulized
Colistin)
(n = 21)		Group B
(Treated without
Nebulized)
Colistin
(n = 38)		p-Value
Mortality
Total Mortality at 28 days * (n, %)11 (52.4%)30 (78.9%)0.034
Mortality at 28 days related to infection * (n, %)6 (40%)25 (73.5%)0.025
Mortality at 7 days * (n, %)2 (9.5%)18 (47.4%)0.003
Days on MV ∞ median (min–max)28 (11–56)17 (1–115))0.053
Ventilator free days @28 d (n, %)4 (19%)2 (7.8%)0.465
Median min–max9 (4–18)18.5 (17–20)0.587
ICU days median (min–max)30 (11–106)17 (1–144)0.007
Morbidity related to A. baumannii infection (n, %)8 (38.1%)8 (21.1%)0.159
Free of symptoms at day 7 *9 (45%)10 (26.3%)0.233
Free of vasopressors at day 7 *6 (28.6%)3 (8.1%)0.039
Resolution of sepsis at day 7 *8 (38.1%)5 (13.5%)0.023
Microbial cure at day 7 *9 (45%)10 (26.3%)0.150
Complications related to A. baumanii infection (n, %)
Sepsis19 (90.5%)36 (94.7%)0.533
Shock14 (66.7%)33 (86.8%)0.065
Cardiomyopathy ∫1 (4.8%)3 (8.1%)0.629
AKI ∞,∫7 (33.3%)15 (40.5%)0.587
Coagulopathy ∫13 (61.9%)29 (76.3%)0.242
Hepatic dysfunction ∫11 (52.4%)19 (50%)0.861
ARDS ∞,∫18 (85.7%)36 (94.7%)0.233
CRRT ∞,∫2 (9.5%)4 (10.8%)0.877
∞ Abbreviations: ARDS, Acute Respiratory Distress Syndrome; AKI, Acute Kidney Injury; CRRT, Continuous Renal Replacement Therapy; MV, mechanical ventilation. ∫ Coagulopathy was defined as a platelet count < 150 × 103/μL or an INR > 1.4. Cardiomyopathy was defined as new onset left ventricular systolic dysfunction during the septic episode. Hepatic dysfunction was considered when total bilirubin was >2 mg/dL. AKI was defined by the KDIGO criteria. * Total mortality at 7 days and total mortality at 28 days were defined as death occurring between the day of a positive blood culture for A. baumannii up until 7 or 28 days, respectively. Mortality was attributed to A. baumannii if at least two intensive care physicians decided that the patient died from septic shock caused by the A. baumannii infection. Free of symptoms by day 7 was defined as resolution of symptoms and improvement of oxygenation by day 7 post the A. baumannii positive blood culture, free of vasopressors by day 7 was defined as the patient not receiving any vasopressors on the seventh day post the bacteremia. Microbiological cure by day 7 was defined as A. baumannii not growing in follow-up blood cultures by day 7. Resolution of sepsis was defined as a SOFA score on day 7 ≤ 24 h before the sepsis-onset SOFA plus maximum one more point.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Andrianopoulos, I.; Kazakos, N.; Lagos, N.; Maniatopoulou, T.; Papathanasiou, A.; Papathanakos, G.; Koulenti, D.; Toli, E.; Gartzonika, K.; Koulouras, V. Co-Administration of High-Dose Nebulized Colistin for Acinetobacter baumannii Bacteremic Ventilator-Associated Pneumonia: Impact on Outcomes. Antibiotics 2024, 13, 169. https://doi.org/10.3390/antibiotics13020169

AMA Style

Andrianopoulos I, Kazakos N, Lagos N, Maniatopoulou T, Papathanasiou A, Papathanakos G, Koulenti D, Toli E, Gartzonika K, Koulouras V. Co-Administration of High-Dose Nebulized Colistin for Acinetobacter baumannii Bacteremic Ventilator-Associated Pneumonia: Impact on Outcomes. Antibiotics. 2024; 13(2):169. https://doi.org/10.3390/antibiotics13020169

Chicago/Turabian Style

Andrianopoulos, Ioannis, Nikolaos Kazakos, Nikolaos Lagos, Theodora Maniatopoulou, Athanasios Papathanasiou, Georgios Papathanakos, Despoina Koulenti, Eleni Toli, Konstantina Gartzonika, and Vasilios Koulouras. 2024. "Co-Administration of High-Dose Nebulized Colistin for Acinetobacter baumannii Bacteremic Ventilator-Associated Pneumonia: Impact on Outcomes" Antibiotics 13, no. 2: 169. https://doi.org/10.3390/antibiotics13020169

APA Style

Andrianopoulos, I., Kazakos, N., Lagos, N., Maniatopoulou, T., Papathanasiou, A., Papathanakos, G., Koulenti, D., Toli, E., Gartzonika, K., & Koulouras, V. (2024). Co-Administration of High-Dose Nebulized Colistin for Acinetobacter baumannii Bacteremic Ventilator-Associated Pneumonia: Impact on Outcomes. Antibiotics, 13(2), 169. https://doi.org/10.3390/antibiotics13020169

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop